



GP 1656

INFORMATION DISCLOSURE STATEMENT CHECKLIST

Client and Matter Name: _____ PG 100

Client #/ Matter #: _____ 082440/00002

Attorney and Due Date Pabst

Check Requested N/A

I have checked the following sources for references to be cited in the IDS and/or
Supplemental IDS:

RECEIVED

SEP 25 2002

TECH CENTER 1600/2900

☒ Application and PTO Correspondence File

☒ Application

☐ IDS/ Supp. IDS

☐ Office Action/ PTO-892

☐ Other _____

☐ PCT File

☐ PCT Written Opinion

☐ International Search Report

☒ Other PG 100 European Search Report [G&C folder]

Suggestions/Requests for other sources: _____

Erica C. Boughner



#5
NW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicants: Abraham J. Domb

SEP 25 2002

Serial No.: 10/044,538

Art Unit: 1636

TECH CENTER 1600/2900

Filed: January 10, 2002

Examiner: Not Yet Assigned

For: *CATIONIC POLYSACCHARIDE COMPOSITIONS*

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits an Information Disclosure Statement, including two (2) pages of Form PTO-1449 and copies of twenty-three documents cited therein.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
3,225,012	12-21-1965	Black, et al.	260/78
4,146,515	03-27-1979	Buikema et al.	260/9
5,312,967	05-17-1994	Kieley, et al.	560/180
5,329,044	07-12-1994	Kieley, et al.	562/564
5,434,233	07-18-1995	Kieley, et al.	527/310
5,473,035	12-05-1995	Kieley, et al.	527/312
5,833,230	11-10-1998	Nakagawa, et al.	271/121

Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
WO 95/30020	12-09-1995	Immuno-Designed Molecules	PCT
WO 97/46223	12-11-1997	Genzyme Corporation	PCT
WO 98/27209	06-25-1998	Emory University	PCT
WO 01/07486	02-01-2001	Polygene, Ltd.	PCT
0 370 810	11-23-1989	Nippon Oil and Fats Co.	EP

Publications

BYK & SCHERMAN *Exp. Opin. Ther.* 8(9): 1125-1141 (1998).

DOMB, *et al.*, "Polymers in gene therapy," in Frontiers in Biological Polymer Applications (Ottenbrite, ed.) Technomic: Lancaster, Vol. 2, pp. 1-16 (1999).

KIELY, *et al.*, "Hydroxylated nylons based on unprotected esterified D-glucaric acid by simple condensation reactions," *J. Am. Chem. Soc.* 116: 571-578 (1994).

LEDLEY, "Nonviral gene therapy: The promise of genes as pharmaceutical products," *Human Gene Therapy* 6: 1129-1144 (1995).

LEE, *et al.*, "Self aggregates of hydrophobically modified chitosan for DNA delivery," *Proceed Intl. Symp. Control. Rel. Bioact. Matter* 24: 651-652 (1997).

MAO, *et al.*, "DNA-chitosan nanospheres: derivitization and storage stability," *Proc. Intl. Symp. Control Rel. Bioact. Matter* 24: 671-672 (1997).

RICHARDSON, *et al.*, "Evaluation of highly purified chitosan as a potential gene delivery vector," *Proceed Intl. Symp. Control Rel. Bioact. Matter* 24: 649-650 (1997).

TAKAKURA, *et al.*, "Control of pharmaceutical properties of soybean tyrosine inhibitor by conjugation with dextran 1: synthesis and characterization," *J. Pharm. Sci.* 78(2): 117-121 (1999).

TRECO & SELDEN, "Non viral gene therapy," *Molec. Med. Today* 1(7):299-348 (1995).


WALSH, *et al.*, "Combination of drug and gene delivery by gelatin nanospheres for the treatment of cystic fibrosis," *Proc. Intl. Sym. Control. Rel. Bioact. Mater.* 24: 75-76 (1997).

YAMAOKA, *et al.*, "Effect of cation content of polycation-type gene carriers on *in vitro* gene transfer," *Chemistry Letters*, 1171-1172 (1998).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

A handwritten signature in dark ink, appearing to be 'Pabst', written over a horizontal line.

Patrea L. Pabst
Reg. No. 31,284


Dated: September 20, 2002

HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8473
FAX 404-817-8588

Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: September 20, 2002



Erica C. Boughner

ATL1 #526728 v1